Golden has been acquired by ComplyAdvantage.Read about it here ⟶

List of Retrotope Inc. patents

List of Retrotope Inc. patents

List of Medrobotics patents

List of Genesis Microchip patents

List of Glen Raven, Inc. patents

Social media companies in California

Clinical Studies Sponsored by Montana State University

Patents where

Current Assignee

Name

is

Retrotope Inc.

	Name	Description	Patent Applicant	Current Assignee	Inventor	Patent Jurisdiction	Patent Number	Date of Patent
	‌ US Patent 11447441 Site-specific isotopic labeling of 1,4-diene systems	Patent 11447441 was granted and assigned to Retrotope Inc. on September, 2022 by the United States Patent and Trademark Office.	Retrotope Inc.	Retrotope Inc.		United States Patent and Trademark Office	11447441	September 20, 2022
	‌ US Patent 11285125 Oxidative retinal diseases	Patent 11285125 was granted and assigned to Retrotope Inc. on March, 2022 by the United States Patent and Trademark Office.	Retrotope Inc.	Retrotope Inc.		United States Patent and Trademark Office	11285125	March 29, 2022
	‌ US Patent RE49238 Alleviating oxidative stress disorders with PUFA derivatives	Patent RE49238 was granted and assigned to Retrotope Inc. on October, 2022 by the United States Patent and Trademark Office.	Retrotope Inc.	Retrotope Inc.		United States Patent and Trademark Office	RE49238	October 11, 2022
	‌ US Patent 10577304 Site-specific isotopic labeling of 1,4-diene systems	Patent 10577304 was granted and assigned to Retrotope Inc. on March, 2020 by the United States Patent and Trademark Office.	Retrotope Inc.	Retrotope Inc.		United States Patent and Trademark Office	10577304	March 3, 2020
	‌ US Patent 11510888 Alleviating oxidative stress disorders with PUFA derivatives	Patent 11510888 was granted and assigned to Retrotope Inc. on November, 2022 by the United States Patent and Trademark Office.	Retrotope Inc.	Retrotope Inc.		United States Patent and Trademark Office	11510888	November 29, 2022
	‌ US Patent 10052299 Alleviating oxidative stress disorders with PUFA derivatives	Patent 10052299 was granted and assigned to Retrotope Inc. on August, 2018 by the United States Patent and Trademark Office.		Retrotope Inc.		United States Patent and Trademark Office	10052299	August 21, 2018
	‌ US Patent 10058522 Oxidative retinal diseases	Patent 10058522 was granted and assigned to Retrotope Inc. on August, 2018 by the United States Patent and Trademark Office.		Retrotope Inc.		United States Patent and Trademark Office	10058522	August 28, 2018
	‌ US Patent 10154983 Neurodegenerative disorders and muscle diseases implicating PUFAs	Patent 10154983 was granted and assigned to Retrotope Inc. on December, 2018 by the United States Patent and Trademark Office.		Retrotope Inc.		United States Patent and Trademark Office	10154983	December 18, 2018
	‌ US Patent 10058612 Impaired energy processing disorders and mitochondrial deficiency	Patent 10058612 was granted and assigned to Retrotope Inc. on August, 2018 by the United States Patent and Trademark Office.		Retrotope Inc.		United States Patent and Trademark Office	10058612	August 28, 2018
	‌ US Patent 10015979 Isotopically modified compounds and their use as food supplements	Patent 10015979 was granted and assigned to Retrotope Inc. on July, 2018 by the United States Patent and Trademark Office.	Retrotope Inc.	Retrotope Inc.		United States Patent and Trademark Office	10015979	July 10, 2018
	‌ US Patent 11510889 Methods for inhibiting the progression of neurodegenerative diseases		Retrotope Inc.	Retrotope Inc.		United States Patent and Trademark Office	11510889	November 29, 2022
	‌ US Patent 11351143 Methods of treating amyotrophic lateral sclerosis	Patent 11351143 was granted and assigned to Retrotope Inc. on June, 2022 by the United States Patent and Trademark Office.	Retrotope Inc.	Retrotope Inc.		United States Patent and Trademark Office	11351143	June 7, 2022
	‌ US Patent 11491130 Methods of treating amyotrophic lateral sclerosis	Patent 11491130 was granted and assigned to Retrotope Inc. on November, 2022 by the United States Patent and Trademark Office.	Retrotope Inc.	Retrotope Inc.		United States Patent and Trademark Office	11491130	November 8, 2022
	‌ US Patent 10730821 Site-specific isotopic labeling of 1,4-diene systems	Patent 10730821 was granted and assigned to Retrotope Inc. on August, 2020 by the United States Patent and Trademark Office.	Retrotope Inc.	Retrotope Inc.		United States Patent and Trademark Office	10730821	August 4, 2020
	‌ US Patent 11166930 Isotopically modified components and therapeutic uses thereof	Patent 11166930 was granted and assigned to Retrotope Inc. on November, 2021 by the United States Patent and Trademark Office.	Retrotope Inc.	Retrotope Inc.		United States Patent and Trademark Office	11166930	November 9, 2021
	‌ US Patent 11241409 Neurodegenerative disorders and muscle diseases implicating PUFAs	Patent 11241409 was granted and assigned to Retrotope Inc. on February, 2022 by the United States Patent and Trademark Office.	Retrotope Inc.	Retrotope Inc.		United States Patent and Trademark Office	11241409	February 8, 2022
	‌ US Patent 10154978 Disorders implicating PUFA oxidation	Patent 10154978 was granted and assigned to Retrotope Inc. on December, 2018 by the United States Patent and Trademark Office.		Retrotope Inc.		United States Patent and Trademark Office	10154978	December 18, 2018
	‌ US Patent 10029956 Therapies for cancer using isotopically substituted lysine	Patent 10029956 was granted and assigned to Retrotope Inc. on July, 2018 by the United States Patent and Trademark Office.		Retrotope Inc.		United States Patent and Trademark Office	10029956	July 24, 2018

18 results

0 selected

18 results

0 selected